Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 6
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
Authors Serefoglu E, Tandogdu Z
Published 16 May 2010 Volume 2010:6 Pages 219—223
DOI https://doi.org/10.2147/TCRM.S7245
Review by Single anonymous peer review
Peer reviewer comments 3
Ege Can Serefoglu1, Zafer Tandogdu2
1Kiziltepe Hospital, Department of Urology, Mardin, Turkey; 2Taksim Teaching Hospital, Department of Urology, Istanbul, Turkey
Abstract: Glucocorticoids are essential in treating many disorders and they are widely used in spite of their negative impact on the skeletal system. As bisphosphonates reduce bone resorption through their action on osteoclasts, they play an important role in management of glucocorticoid-induced osteoporosis. Unlike other bisphosphonates, zoledronic acid is given by intravenous infusion and it has a potential advantage of increasing the compliance and adherence of patients when it is given 5 mg once a year. However, this treatment modality seems to be associated with more adverse events than oral administrations, and further studies with longer follow-up periods must be conducted to determine the safety and cost-effectiveness of long-term treatment with zoledronic acid.
Keywords: bisphosphonates, glucocorticoids, osteoporosis, zoledronic acid
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.